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BOOK REVIEW 
 
GLOBAL PHARMACEUTICAL POLICY: 
ENSURING MEDICINES FOR TOMORROW’S WORLD 
Frederick M Abbott and Graham Dukes 
Cheltenham UK and Northampton USA: Edward Elgar Publishing, 2009, 320 pp, 
£75.00, ISBN  9781848440906 (hbk) 
 
How can we ensure that safe and effective pharmaceutical products are available and 
affordable to those who need them, both in the developed and developing worlds? 
This is the central research question pursued by the eminent scholars Abbott and 
Dukes in their timely, ambitious and informative book.   
The question posed by the authors is of obvious importance, but is unfortunately 
difficult to answer.  The pharmaceutical industry is complex and subject to regulation 
from many angles.  Tinkering with this regulatory framework could upset the delicate 
balance of private and public interests that has been forged, bringing adverse 
consequences for industry and patients alike.  Nevertheless, the authors, ably assisted 
by contributions from expert participants at a roundtable meeting held at Florida State 
University in 2007, have done a superb job in identifying the weaknesses and tensions 
in current policies and suggesting practical reforms thereof. 
Abbott and Dukes‟ analysis unfolds over ten chapters, each of which is discrete yet 
interlinked.  In chapter one, the authors provide a helpful summary of the structure of 
the book and introduce its main arguments.  Chapters two and three are closely 
connected and examine how pharmaceutical innovation is encouraged and new drugs 
developed and brought to market. 
Chapter two (“Promoting innovation: patents, subsidies and prizes”) focuses on the 
role of the patent system in stimulating investment in pharmaceutical research.  
Patents, and indeed market-based incentives in general, are viewed by Abbott and 
Dukes in this context as being a double-edged sword. Drug development is an 
expensive and commercially risky affair. Without the lure of potentially massive 
profits gathered during the period of patent protection, less money would be invested 
in the pharmaceutical sector. 
Yet, Abbott and Dukes argue, the very same incentive structures can work against the 
public interest by actually encouraging sub-optimal levels of innovation.  For 
example, rather than following the high risk, high reward strategy of attempting to 
design truly innovative “blockbuster” drugs, pharmaceutical companies may instead 
choose to play safe by spending smaller amounts of money to achieve minor 
improvements to existing drugs. The improved versions can be patented, thereby 
extending the originator company‟s monopoly term and restricting competition from 
generic manufacturers (a practice known as “evergreening”). Market incentives also 
skew research programmes towards the most profitable markets, such as those for so-
called “lifestyle” diseases that affect those in wealthier countries. Diseases such as 
sleeping sickness that ravage poorer countries are commercially unattractive and 
therefore largely ignored by the private sector.  
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Some of the strategies for addressing these problems involve the recalibration of the 
patent system itself.  For example, raising the bar on the inventive step requirement in 
patent law could incentivise companies to direct their research budgets towards 
creating truly breakthrough new drugs (rather than modest incremental improvements 
on existing drugs). The authors also weigh up the possible benefits of creating a 
“tiered” patent system. Under this regime, small improvements to existing drugs 
would only be eligible for weaker forms of intellectual property protection through 
“utility models” or “petty patents”.  By contrast, more groundbreaking drugs could 
receive the full twenty years of strong patent protection.  Other proposals include the 
use of “carrots” other than patents to stimulate pharmaceutical innovation, such as 
granting subsidies to those prepared to embark on a particular line of research or 
awarding prizes to those who achieve its successful completion.  
In chapter three (“Policies on innovation: past, present and future”), the authors 
present statistical data which shows a marked decline in rates of pharmaceutical 
innovation (defined by the numbers of “radical innovations” and “innovations related 
to existing drugs” entering the market) since the mid-1980s.  Abbott and Dukes seek 
to elucidate the possible reasons behind this trend.  They suggest that the rising costs 
of research and marketing, or the consolidation of industry into a small number of 
large firms may have played a causal role.  Another explanation is the “low hanging 
fruit” hypothesis.  This is the idea that much of what can be achieved through small-
molecule chemistry has now already been “picked”.  Future innovation may therefore 
require novel and more complex approaches.  Building on this point, the authors 
discuss the promise of biotechnology to raise levels of innovative output, and consider 
the regulatory approaches that might best facilitate such progress. 
Abbott and Dukes reject the claim that burdensome regulatory requirements, such as 
the need to assess the effects of a drug through toxicological and clinical studies, have 
deterred innovation. They go on in chapter four (“The global regulatory environment: 
quality, safety and efficacy”) to analyse in more detail the system for approval of new 
drugs.  Historical background is provided in relation to the emergence of dedicated 
drug regulatory agencies, such as the US Food and Drug Administration (FDA), 
which were set up, despite strong opposition from industry, to protect the public by 
ensuring that drugs are safe and effective. 
What degree of safety and efficacy are people entitled to expect when they take 
approved medicines?  Clearly, absolute standards are unrealistic, as no medicine is 
entirely safe or 100% effective.  Regulatory approval, therefore, signifies that a drug 
is deemed “sufficiently” or “reasonably” safe and effective, given its known benefits 
and side-effects and the severity of the condition(s) for which it is indicated.  Yet, in 
addition to these known risks that patients must accept, drugs may carry unforeseen 
risks that cannot be detected during clinical trials.  It is therefore vital that effective 
systems are put in place to monitor adverse drug reactions.  Abbott and Dukes 
question whether the reporting of adverse reactions to the authorities should be the 
subject of legal obligation or dependent on the good faith of reporters, and favour the 
latter approach. 
Data confidentiality is a further area of concern in relation to the drug approval 
process.  This privilege may be abused by companies hoping to extend their period of 
market exclusivity by delaying the entry of generic drugs into the market.  More 
worryingly, control over proprietary data can be used to suppress evidence of adverse 
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effects revealed during clinical trials.  Legal solutions to both of these problems are 
explored. 
Chapter five (“Medicines for the developing world”) provides a systematic discussion 
of the myriad problems that can limit access to safe and effective medicines in 
developing countries.  The TRIPS Agreement and the restrictive intellectual property 
clauses in free trade agreements present one set of barriers.  Other challenges include 
patchy infrastructure for the procurement, inspection and distribution of drugs and the 
lack of R&D targeted towards the health needs of poorer countries. Abbott and Dukes 
cite the emergence of the “essential drugs” concept (as embodied in the “Model List 
of Essential Drugs” of the World Health Organization (WHO)) and public-private 
partnerships (such as the Gates Foundation “Medicine for Malaria” venture) as 
examples of valuable strategies worthy of further support. 
The later chapters of the book examine some of the less frequently discussed but 
nevertheless important areas of pharmaceutical policy. Chapter six (“The use of 
medicines: education, information and persuasion”) casts a critical eye over the ways 
information regarding drug safety and efficacy is conveyed to health professionals 
and the public.  It is in this chapter that the influence of industry perhaps seems most 
insidious and corrosive.  Examples of dubious practices abound.  Medical journals 
that publish articles critical of the exaggerated claims of drug advertisements face 
punishment in the (somewhat ironic) form of advertising boycotts.  Physicians are 
visited by pharmaceutical representatives (a role which is apparently, in the United 
States, often filled by attractive young women) who build relationships of trust and 
employ sales techniques to attempt to influence prescribing practice.  Gifts, lunches 
and even all-expenses paid trips to attend symposia in exotic locations may be offered 
to doctors as part of the promotional activities of a drug company.  Abbott and Dukes 
do not argue that drug marketing should be halted altogether.  They do, however, 
offer suggestions as to how to counter the industry‟s more questionable techniques of 
persuasion and restore objectivity to the information environment.  
Chapter seven (“Regulation and the role of the courts”) discusses, inter alia, civil 
litigation against pharmaceutical companies on the grounds of misleading advertising 
or drug-related injury.  Abbott and Dukes argue that litigation serves a number of 
useful social functions in this context.  It can protect the interests of individual 
plaintiffs by providing compensation for harm.  It can also promote the broader public 
interest by deterring misconduct and providing a forum in which information on 
product safety might come to light. The authors are therefore critical of the growing 
acceptance of the US tort law doctrine of “pre-emption” (whereby approval by a drug 
regulatory agency shields a manufacturer from civil liability) which they suggest 
would deprive society of these benefits. 
Chapter eight (“Specialized policy areas: vaccines biologicals and blood products; 
alternative and traditional medicines; self-medication; counterfeit medicines”) 
provides analysis of various policy sub-fields that merit separate consideration. 
Chapter nine (“The rich, the poor and the neglected”) highlights the problem of over-
subscription of medicines, which raises concerns from the perspectives of public 
health and economic waste.  Abbott and Dukes also survey the measures adopted in 
France and the United States to encourage research into rare and neglected diseases 
(also referred to as „orphan diseases‟).  Although these initiatives have yielded some 
success stories, the authors observe that further fine-tuning may be necessary to 
prevent abuse in the form of inappropriate profiteering. 
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In the final chapter (“Global and regional policies: the way ahead”), the various 
strands of the book are drawn together and suggestions are made for the definition of 
future policy objectives.  The “global” in the title of the book is brought to the fore in 
discussions of the pros and cons of “global solutions”.  One idea floated by Abbott 
and Dukes is the establishment of a global drug regulatory agency, perhaps operating 
under the auspices of the WHO, which could maintain uniform standards and avoid 
the wasteful duplication of effort involved in drug approval on a country-by-country 
basis. Conceding, however, that this goal may not be achievable in practice, or even 
wholly desirable, the chapter looks at more feasible alternatives, such as the 
continuation of international policy-setting by the WHO through consensus-building 
and the provision of technical support.  It also examines the advantages of regional 
coordination of drugs policy amongst homogenous groups of nations, with examples 
including the Eastern Caribbean Drug Service (ECDS), the Association of South East 
Asian Nations (ASEAN) and the European Medicines Evaluatory Agency (EMEA). 
The discussion concludes with reiteration of the core messages from the previous 
chapters. 
Abbott and Dukes have produced a book that is holistic in its approach and forward 
thinking in its outlook. It is written in a clear and erudite style and manages to provide 
detailed analysis without ever losing sight of the “big picture”.  As the authors 
themselves point out, there are no magic solutions to the complex problems in this 
field.  Nevertheless, this work provides an excellent framework for thinking about the 
strengths and deficiencies of the current system and advances powerful arguments in 
favour of joined-up thinking and smarter regulation.  The book is essential reading for 
students, academics, practitioners and policy-makers interested in the future of 
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